Connecticut Epidemiologist



January 2022 Vol. 42, No. 1

Reportable Diseases, Emergency Illnesses and Health Conditions, and Reportable Laboratory Findings for 2022

In accordance with Conn. Gen. Stat. §19a-2a and Conn. Agencies Regs. §19a-36-A2, the Commissioner of the Department of Public Health (DPH) shall issue a list of reportable diseases, emergency illnesses and health conditions and a list of reportable laboratory findings on an annual basis. For 2022, there are no changes to the lists, aside from some minor technical edits and clarifications.

Disease reporting is required under Conn. Agencies Regs. §19a-36-A3 and Conn. Agencies Regs. §19a-36-A4 (see back of form) and Conn. Gen. Stat. §19a-2a and §19a-215 Statutes, using the designated forms. To reduce the use of paper forms and improve the timeliness of disease reporting, we encourage providers to use secure electronic fax (efax) for reporting instead of mailing.

Fast Track Initiative

Since 2017, the State Public Health Laboratory (SPHL) has conducted testing for carbapenemresistant Enterobacteriaceae (CRE), carbapenem resistant Acinetobacter baumannii (CRAB), and a subset of carbapenem resistant Pseudomonas aeruginosa (CRPA) isolates submitted by clinical laboratories. Under the new SPHL Fast Track Initiative for difficult-to-treat infections, all CRAB isolates, and reportable CRE isolates found to harbor a non-KPC carbapenemase (NDM, Oxa48, IMP or VIM) (or those CRE isolates that have strong clinical indicators that this is likely) will be eligible for on-demand testing services, including facilitation courier services and testing performed 7 days per week. Isolates received before noon will receive carbapenemase testing on the day of receipt, followed by antimicrobial susceptibility testing the following day. All isolates not eligible for Fast Track will be

INSIDE	Page
Reportable Diseases, Emergency Illnesses and Health Conditions , and Laboratory Findings for 2022	1
Fast Track Initiative	1
List of Reportable Diseases, Emergency Illnesses and Health Conditions—2022	2
List of Reportable Laboratory Findings—2022	3
Persons Required to Report Reportable Diseases, Emergency Illnesses and Health Conditions, and Reportable Laboratory Findings	4

processed via the Standard Pathway with testing performed twice per week.

Questions regarding laboratory testing can be directed to Diane Noel by email diane.noel@ct.gov or phone 860-920-6550 (or 860-716-2705 on weekends and holidays).

Questions regarding antimicrobial resistance surveillance can be directed to Meghan Maloney, meghan.maloney@ct.gov or phone 860-840-1867.

For Public Health Emergencies
After 4:30 PM on Weekends
or Holidays, call the
Department of Public Health at
860-509-8000

CONTACT INFORMATION

Connecticut Department of Public Health Infectious Diseases Division 410 Capitol Avenue/MS#11FDS Hartford, CT 06134

Phone: 860-509-7995 Fax: 860-509-7910

REPORTABLE DISEASES, EMERGENCY ILLNESSES and HEALTH CONDITIONS - 2022 PART A: REPORTABLE DISEASES

Physicians, and other professionals are required to report using the Reportable Disease Confidential Case Report form (PD-23), other disease specific form or authorized method (see page 4 for additional information). Forms can be found on the DPH "Forms" webpage or by calling 860-509-7994. Mailed reports must be sent in envelopes marked "CONFIDENTIAL."

Category 1 Diseases: Report immediately by telephone (860-509-7994) on the day of recognition or strong suspicion of disease

for those diseases marked with a telephone (2). On evenings, weekends, and holidays call 860-509-8000.

These diseases must also be reported by mail (or fax) within 12 hours.

Category 2 Diseases: All other diseases not marked with a telephone must be reported by mail (or fax) within 12 hours of

recognition or strong suspicion of disease.

Acquired Immunodeficiency Syndrome (1,2) Hepatitis B:

Acute flaccid myelitis

Acute HIV infection

Anthrax

Babesiosis

Borrelia miyamotoi disease

Botulism

Brucellosis

California group arbovirus infection

Campylobacteriosis

Candida auris

Chancroid

Chickenpox Chickenpox-related death

Chikungunya

Chlamydia (C. trachomatis) (all sites)

Cholera

Coronavirus disease 2019 (COVID-19)

COVID-19 Hospitalizations

Cryptosporidiosis

Cyclosporiasis

Dengue

Tiphtheria

E-cigarette or vaping product use associated lung injury (EVALI)

Eastern equine encephalitis virus infection

Ehrlichia chaffeensis infection

Escherichia coli O157:H7 gastroenteritis

Gonorrhea

Group A Streptococcal disease, invasive (3) Group B Streptococcal disease, invasive (3)

Haemophilus influenzae disease, invasive (3)

Hansen's disease (Leprosy)

Healthcare-associated Infections (4)

Hemolytic-uremic syndrome (5)

Hepatitis A

acute infection (2)

HBsAg positive pregnant women

Hepatitis C:

acute infection (2)

• perinatal infection

positive rapid antibody test result

HIV-1 / HIV-2 infection in: (1)

persons with active tuberculosis disease

• persons with a latent tuberculous

• persons of any age

• pregnant women

HPV: biopsy proven CIN 2, CIN 3 or AIS or their equivalent (1)

Influenza-associated death (6)

Influenza-associated hospitalization (6)

Legionellosis

Listeriosis

Lyme disease

Malaria

Measles

Melioidosis

Meningococcal disease

Mercury poisoning

Multisystem inflammatory syndrome in

children (MIS-C)

Mumps

Neonatal bacterial sepsis (7)

Neonatal herpes (≤ 60 days of age)

Occupational asthma

TOutbreaks:

Foodborne (involving ≥ 2 persons)

Institutional

Unusual disease or illness (8)

Pertussis

Plague

Pneumococcal disease, invasive (3)

Poliomyelitis

Powassan virus infection

C fever

Rabies

Ricin poisoning

Rocky Mountain spotted fever

Rubella (including congenital)

Salmonellosis

SARS-CoV

Shiga toxin-related disease (gastroenteritis)

Shigellosis

Silicosis

Smallpox

St. Louis encephalitis virus infection

Staphylococcal enterotoxin B pulmonary poisoning

Staphylococcus aureus disease, reduced or

resistant susceptibility to vancomycin (1) Staphylococcus aureus methicillin-

resistant disease, invasive, community acquired (3,9)

Staphylococcus epidermidis disease, reduced or resistant susceptibility to vancomycin (1)

Syphilis

Tetanus

Trichinosis

Tuberculosis

Tularemia

Typhoid fever Vaccinia disease

Tenezuelan equine encephalitis virus infection

Vibrio infection (parahaemolyticus, vulnificus, other)

Tiral hemorrhagic fever

West Nile virus infection Yellow fever

FOOTNOTES: (NOTE: a footnote was removed, and they have been renumbered)

- Report only to State.
- As described in the CDC case definition.
- Invasive disease: from sterile fluid (blood, CSF, pericardial, pleural, peritoneal, joint, or vitreous) bone, internal body sites, or other normally sterile site including muscle.
- Report HAIs according to current CMS pay-for-reporting or pay-for-performance requirements. Detailed instructions on the types of HAIs, facility types and locations, and methods of reporting are available on the DPH website: https://portal.ct.gov/ DPH/HAI/Healthcare-Associated-Infections-Reporting-Requirements
- 5. On request from the DPH and if adequate serum is available, send serum from patients with HUS to the DPH Laboratory for antibody testing.
- Submit the Hospitalized and Fatal Cases of Influenza form as specified. For influenza Hospitalizations, Electronic Medical Record access is required.
- 7. Clinical sepsis and blood or CSF isolate obtained from an infant ≤ 72 hours of age.
- 8. Individual cases of "significant unusual illness" are also reportable.
- 9. Community-acquired: infection present on admission to hospital, and person has no previous hospitalizations or regular contact with the health-care setting.

How to report: The PD-23 is the general disease reporting form and should be used if other specialized forms are not available. The PD-23 can be found on the DPH "Forms" webpage (https://portal.ct.gov/DPH/Communications/Forms/Forms). It can also be ordered by writing the Department of Public Health, 410 Capitol Ave., MS#11FDS, P.O. Box 340308, Hartford, CT 06134-0308 or by calling the Epidemiology and Emerging Infections Program (860-509-7994). Specialized reporting forms are available on the DPH "Forms" webpage or by calling the following programs: Epidemiology and Emerging Infections Program (860-509-7994) - Hospitalized and Fatal Cases of Influenza, Healthcare Associated Infections (860-509-7995) - National Healthcare Safety Network, HIV/AIDS Surveillance (860-509-7900) - Adult HIV Confidential Case Report form, Immunizations Program (860-509-7929) - Chickenpox Case Report (Varicella) form, Occupational Health Surveillance Program (860-509-7740) - Physician's Report of Occupational Disease, Sexually Transmitted Disease Program (860-509-7920), and Tuberculosis Control Program (860-509-7722). National notifiable disease case definitions are found on the CDC website.

Telephone reports of Category 1 disease should be made to the local Director of Health for the town in which the patient resides, and to the Epidemiology and Emerging Infections Program (860-509-7994). Tuberculosis cases should be directly reported to the Tuberculosis Control Program (860-509-7722). For the name, address, or telephone number of the local Director of Health for a specific town contact the Office of Local Health Administration (860-509-7660).

For public health emergencies on evenings, weekends, and holidays call 860-509-8000.

REPORTABLE LABORATORY FINDINGS - 2022

The director of a clinical laboratory must report laboratory evidence suggestive of reportable diseases (see page 4 for additional information). The Laboratory Report of Significant Findings form (OL-15C) can be found on the DPH "Forms" webpage or by calling 860-509-7994.

Anaplasma phagocytophilum by PCR only	Listeria monocytogenes (1) □ Culture □ PCR
Babesia: ☐ IFA IgM (titer) IgG (titer) ☐ Blood smear ☐ PCR ☐ Other	Mercury poisoning $\square \text{ Urine } \ge 35 \text{ µg/g creatinine } \underline{\qquad} \text{µg/g}$
□ microti □ divergens □ duncani □ Unspeciated	\square Blood \ge 15 µg/L µg/L
Bordetella pertussis (titer)	Mumps virus (12) (titer)
□ Culture (1) □ Non-pertussis Bordetella (1) (specify)	Mycobacterium leprae
□ DFA □ PCR	Mycobacterium tuberculosis Related Testing (1)
Borrelia burgdorferi (2)	AFB Smear ☐ Positive ☐ Negative
Borrelia miyamotoi	If positive ☐ Rare ☐ Few ☐ Numerous
California group virus (3) spp Campylobacter (3) spp Culture PCR EIA	NAAT □ Positive □ Negative □ Indeterminate Culture □ Mycobacterium tuberculosis □ Non-TB mycobacterium (specify M
Candida auris [report samples from all sites] (1)	Culture \square <i>Mycobacterium tuberculosis</i>
Candida spp. [blood isolates only]: (1,3)	I Non-1D mycobacterium. (specify M.)
Candida spp. [blood isolates only]: (1,3) Carbapenem-resistant Acinetobacter baumannii (CRAB) (1,4)	Neisseria gonorrhoeae (test type)
Carbapenem-resistant Enterobacterales (CRE) (1,3,4)	Neisseria meningitidis, invasive (1,4)
Genus spp Carboxyhemoglobin $\geq 5\%$ (2) % COHb	Culture Other
Carboxynemoglobin \geq 5% (2)% COHb Chikungunya virus	Neonatal bacterial sepsis (3,13) spp
Chlamydia trachomatis (test type)	Poliovirus
Clostridium difficile (5)	Powassan virus
Corvnehacterium dinhtheria (1)	Rabies virus
Cryptosporidium spp (3) \square PCR \square DFA \square EIA	Rickettsia rickettsia □ PCR □ IgG titers ≥1:128 only □ Culture
☐ Microscopy ☐ Other:	Respiratory syncytial virus (2)
Cyclospora spp (3) ☐ PCR ☐ Microscopy ☐ Other:	Rubella virus (12) (titer)
Dengue virus	Rubeola virus (Measles) (12) (titer)
Eastern equine encephalitis virus	St. Louis encephalitis virus
Ehrlichia chaffeensis □ PCR □ IgG titers ≥1:128 only □ Culture Enterotoxigenic Escherichia coli (ETEC) □ Culture □ PCR	Salmonella (1,3)(serogroup & type) ☐ Culture ☐ PCR
Escherichia coli O157(1) □ Culture □ PCR	SARS-CoV (1) \square IgM/IgG \square PCR (specimen) \square Other
Giardia spp (3)	□ PCR (specimen) □ Other
Group A <i>Streptococcus</i> , invasive (1,4)	SARS-CoV2
Group B Streptococcus, invasive (1,4) Culture Other	□ Positive □ Negative
Haemophilus ducreyi	Shiga toxin (1) ☐ Stx1 ☐ Stx2 ☐ Type Unknown
Haemophilus influenzae, invasive (1,4) □ Culture □ Other	□ PCR □ EIA
Hepatitis A virus (HAV): □ IgM anti-HAV (7) □ NAAT Positive (6)	Shigella (1,3) (serogroup/spp)
ALT Total Bilirubin	Staphylococcus aureus, invasive (4) ☐ Culture ☐ Other methicillin-resistant ☐ methicillin-sensitive
Hepatitis B HBsAg	Staphylococcus aureus, vancomycin MIC \geq 4 µg/mL (1)
☐ IgM anti-HBc ☐ HBeAg (2) ☐ HBV DNA (2)	MIC to vancomycin μg/mL
anti-HBs (7) ☐ Positive (titer) ☐ Negative Hepatitis C virus (HCV) (8) ☐ Antibody ☐	Staphylococcus epidermidis, vancomycin MIC \geq 32 µg/mL (1)
☐ PCR/NAAT/RNA ☐ Genotype specify	MIC to vancomycin µg/mL
Herpes simplex virus (infants \leq 60 days of age)	Streptococcus pneumoniae
☐ Culture ☐ PCR ☐ IFA ☐ Ag detection	☐ Culture (1,4) ☐ Urine antigen ☐ Other (4) Treponema pallidum ☐ RPR (titer) ☐ FTA ☐ EIA
HIV Related Testing (report only to the State) (9)	Treponema pallidum □ RPR (titer) □ FTA □ EIA
☐ Detectable Screen (IA)	□ VDRL (titer) □ TPPA
Antibody Confirmation (WB/IFA/Type-diff) (9)	Trichinella
HIV 1 Positive Neg/Ind HIV 2 Positive Neg/Ind	Varicella-zoster virus, acute
☐ HIV NAAT (or qualitative RNA) ☐ Detectable ☐ Not Detectable ☐ HIV Viral Load (all results) (9)copies/mL	□ Culture □ PCR □ DFA □ Other
☐ HIV genotype (9)	Vibrio (1,3) spp ☐ Culture ☐ PCR
☐ CD4 count: cells/uL;% (9)	West Nile virus Yellow fever virus
HPV (report only to the State) (10)	Yersinia, not pestis $(1,3)$ spp \square Culture \square PCR
Biopsy proven □ CIN 2 □ CIN 3 □ AIS	Zika virus
or their equivalent, (specify)	
Influenza virus: (report only to State) \square Rapid antigen (2) \square RT-PCR	BIOTERRORISM at first clinical suspicion (14) Bacillus anthracis (1) Brucella spp (1)
☐ Type A ☐ Type B ☐ Type Unknown	Bacillus anthracis (1) Burkholderia mallei (1) Burkholderia pseudomallei (1)
□ Subtype Lead poisoning (blood lead \ge 10 μg/dL <48 hrs; 0-9 μg/dL monthly) (11)	Clostridium botulinum Coxiella burnetii
□ Finger stick level µg/dL □ Venous level µg/dL	Francisella tularensis Ricin (1)
Legionella spp (1)	Staphylococcus aureus - enterotoxin B Variola virus (1)
☐ Culture ☐ DFA ☐ Ag positive	Venezuelan equine encephalitis virus Yersinia pestis (1)
☐ Four-fold serologic change (titers)	Viral agents of hemorrhagic fevers (1)
	include with a secretary for CDAD
 Send isolate/specimen to DPH Laboratory. Send laboratory report (electronic or paper) on first identification of an organism. For CRE/CRAB, also include wounds. 	include urine or sputum; for CRAB results are only reportable by electronic file. 10. Upon request from the DPH, send fixed tissue from the
send laboratory report if carbapenem resistance is suggested by laboratory 5. Upon request from the	DPH, report all <i>C. difficile</i> positive diagnostic specimen for HPV typing.
antimicrobial testing. For GBS, send isolate for cases <1 year of age. For stool samples.	11. Report results ≥ 10 µg/dL within 48 hours to the Local Health
	otal Bilirubin results if conducted Department and DPH; submit ALL lead results at least monthly to DPH only.
available. For Shiga toxin-related disease, send positive broth or stool Otherwise, check "Not I	Done". 12. Report all IgM positive titers, only report IgG titers considered
specimen. For <i>Legionella</i> send only isolates. 7. Negative HBsAg and all	anti-HBs results only reportable significant by testing laboratory.
 Only laboratories with electronic file reporting are required to report for children ≤ 2 years ol 	 Report all bacterial isolates from blood or CSF from infants ≤ 72

positive results.

Specify species/serogroup/serotype.

Sterile site: sterile fluids (blood, CSF, pericardial, pleural, peritoneal, joint, or

vitreous), bone, internal body site (lymph node, brain, heart, liver, spleen,

kidney, pancreas, or ovary), or other normally sterile site including muscle.

8. Report positive Antibody, and all RNA and Genotype

results. Negative RNA results only reportable by

Report all HIV antibody, antigen, viral load, and qualitative

NAAT results. HIV genotype (DNA sequence) and all CD4

electronic reporting.

hours of age.

preferred.

and holidays 860-509-8000.

Call the DPH, weekdays 860-509-7994; evenings, weekends,

Report positive and negative results. Electronic reporting

Persons Required to Report Reportable Diseases, Emergency Illnesses and Health Conditions

- 1. Every health care provider who treats or examines any person who has or is suspected to have a reportable disease, emergency illness or health condition shall report the case to the local director of health or other health authority within whose jurisdiction the patient resides and to the Department of Public Health.
- 2. If the case or suspected case of reportable disease, emergency illness or health condition is in a health care facility, the person in charge of such facility shall ensure that reports are made to the local director of health and Department of Public Health. The person in charge shall designate appropriate infection control or record keeping personnel for this purpose.
- 3. If the case or suspected case of reportable disease, emergency illness or health condition is not in a health care facility, and if a health care provider is not in attendance or is not known to have made a report within the appropriate time, such report of reportable disease, emergency illness or health condition shall be made to the local director of health or other health authority within whose jurisdiction the patient lives and the Department of Public Health by:
 - a. the administrator serving a public or private school or day care center attended by any person affected or apparently affected with such disease, emergency illness or health condition;
 - b. the person in charge of any camp;
 - c. the master or any other person in charge of any vessel lying within the jurisdiction of the state;
 - d. the master or any other person in charge of any aircraft landing within the jurisdiction of the state;
 - e. the owner or person in charge of any establishment producing, handling, or processing dairy products, other food or non-alcoholic beverages for sale or distribution;
 - f. morticians and funeral directors

Persons Required to Report Reportable Laboratory Findings

The director of a laboratory that receives a primary specimen or sample, which yields a reportable laboratory finding, shall be responsible for reporting such findings within 48 hours to the local director of health of the town in which the affected person normally resides. In the absence of such information, the reports should go to the town from which the specimen originated and to the Department of Public Health. Reports must include name, address, contact phone number, date of birth, race, ethnicity, gender, and occupation of patient.

IMPORTANT NOTICE

The Reportable Disease Confidential Case Report Form PD-23 can be used to report conditions on the current list, unless there is a specialized form or other authorized method. The Laboratory Report of Significant Findings Form OL-15C can be used by staff of clinical laboratories to report evidence suggestive of reportable diseases or other approved format by DPH. Reporting forms can be found at: (https://portal.ct.gov/DPH/Communications/Forms/Forms) or by calling 860-509-7994. Please follow these guidelines when submitting written reports:

- Forms must include name, address, and phone number of person reporting and healthcare provider, infectious agent, test method, date of onset of illness, and name, address, date of birth, race, ethnicity, gender, and occupation of patient.
- Send the white copy of completed form to DPH via fax (860-920-3131), or mail to: Connecticut Department of Public Health, 410 Capitol Ave., MS#11FDS, P.O. Box 340308, Hartford, CT 06134-0308. Mark envelope with "CONFIDENTIAL".
- Unless otherwise noted, send the yellow copy of the completed report to the Director of Health of the patient's town of residence.
- Keep the pink copy in the patient's medical record.

Connecticut Department of Public Health			
Manisha Juthani, MD	Matthew L. Cartter, MD, MPH	Lynn Sosa, MD	
Commissioner of Public Health	State Epidemiologist	Deputy State Epidemiologist	
Infectious Diseases Programs			
Epidemiology and Emerging Infections	Healthcare Associated Infections & Antimicrobial	HIV & Viral Hepatitis	
860-509-7994	Resistance	860-509-7900	
	860-509-7995		
Immunizations	Sexually Transmitted Diseases	Tuberculosis	
860-509-7929	860-509-7920	860-509-7722	
The Connecticut Epidemiologist Newsletter - (Telecommunications Relay Service 7-1-1)			
Editor: Meghan Maloney, MPH	Assistant Editor: Matthew L. Cartter, MD, MPH	Assistant Editor/ Producer: Chris Heneghan, MPH	